Long-term efficacy and toxicity results of the FLUMIZ trial (fludarabine and mitoxantrone followed by yttrium-90 ibritumomab tiuxetan in untreated follicular lymphoma)

Annals of Oncology

Volumn 23, Issue 3, 2012, Pages 805-807

  Zinzani, P L ^a   Derenzini, E ^a   Pellegrini, C ^a   Rigacci, L ^b   Fabbri, A ^c   Gandolfi, L ^a   Argnani, L ^a   Casadei, B ^a   Pulsoni, A ^d   Gobbi, M ^e   Perotti, A ^f   Zaccaria, A ^g   Voso, M T ^h   Cabras, M G ⁱ   De renzo, A ^j  

^a UNIVERSITY OF BOLOGNA   (Italy)

^b CAREGGI UNIVERSITY HOSPITAL   (Italy)

^c UNIVERSITY HOSPITAL OF SIENA   (Italy)

^d SAPIENZA UNIVERSITY OF ROME   (Italy)

^e UNIVERSITY OF GENOA   (Italy)

^f UNIVERSITY OF ROME TOR VERGATA   (Italy)

^g SANTA MARIA DELLE CROCI HOSPITAL   (Italy)

^h CATHOLIC UNIVERSITY   (Italy)

ⁱ Cagliari Hospital   (Italy)

^j UNIVERSITY OF NAPLES FEDERICO II   (Italy)

more..

Author keywords

[No Author keywords available]

Indexed keywords

FLUDARABINE; IBRITUMOMAB TIUXETAN; MITOXANTRONE; RITUXIMAB;

ACUTE GRANULOCYTIC LEUKEMIA; CANCER COMBINATION CHEMOTHERAPY; CANCER MORTALITY; CANCER REGRESSION; CANCER RELAPSE; CANCER STAGING; DRUG DOSE REGIMEN; DRUG DOSE SEQUENCE; DRUG EFFICACY; DRUG SAFETY; FOLLICULAR LYMPHOMA; HUMAN; LETTER; MAJOR CLINICAL STUDY; MULTICENTER STUDY; MULTIPLE CYCLE TREATMENT; MYELODYSPLASTIC SYNDROME; OVERALL SURVIVAL; PHASE 2 CLINICAL TRIAL; PRIORITY JOURNAL; PROGRESSION FREE SURVIVAL; RADIOIMMUNOTHERAPY; STEM CELL TRANSPLANTATION;

ANTIBODIES, MONOCLONAL; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; DISEASE-FREE SURVIVAL; HUMANS; LYMPHOMA, FOLLICULAR; MITOXANTRONE; RADIOIMMUNOTHERAPY; VIDARABINE;

EID: 84857613613     PISSN: 09237534     EISSN: 15698041     Source Type: Journal    
DOI: 10.1093/annonc/mdr633     Document Type: Letter

References (5)

1. Witzig TE, Gordon LI, Cabanillas F et al. Randomized controlled trial of yttrium-90-labeled ibritumomab tiuxetan radioimmunotherapy versus rituximab immunotherapyfor patients with relapsed or refractory low-grade, follicular, or transformed B-cell non-Hodgkin's lymphoma. J Clin Oncol 2002; 20: 2453-2463.
2. Morschhauser F, Radford J, Van Hoof A et al. Phase III trial of consolidation therapy with yttrium-90-ibritumomab tiuxetan compared with no additional therapy after first remission in advanced follicular lymphoma. J Clin Oncol 2008; 26: 5156-5164.
3. Zinzani PL, Tani M, Pulsoni A et al. Fludarabine and mitoxantrone followed by yttrium-90 ibritumomab tiuxetan in previously untreated patients with follicular non-Hodgkin lymphoma trial: a phase II non-randomised trial (FLUMIZ). Lancet Oncol 2008; 9: 352-358.
4. Jacobs SA, Swerdlow SH, Kant J et al. Phase II trial of shortcourse CHOP-R followed by 90Y-ibritumomab tiuxetan and extended rituximab in previously untreated follicular lymphoma. Clin Cancer Res 2008; 14: 7088-7094.
5. Zinzani PL, Tani H, Pulsoni A et al. A phase II trial of RFM (rituximab, fludarabine and mitoxantrone) chemotherapy followed by yttrium-90 ibritumomab tiuxetan (90Y-IT) for untreated follicular lymphoma (FL) patients. Ann Oncol 2012; 23: 415-420.